GLPG Lakefront Biotherapeutics NV
Price Chart
Executive Summary
Bank of America crossed above the 5% threshold and now holds a 9.30% total economic interest in Lakefront Biotherapeutics, comprising 0.95% direct voting rights and 8.35% via equivalent financial instruments (mostly total return swaps and rights to use). This is a purely passive/regulatory disclosure driven by BofA's market-making and derivatives activity, not an active stake-building signal by a strategic investor or activist.
Actionable Insight
This is a routine regulatory disclosure from a large financial institution, not an activist campaign or strategic stake. Monitor for any subsequent 13D filing or public statement from BofA indicating intent, though no such filing is expected. The stock may see modest short-term noise from algos interpreting the 9.30% headline, but the long position is economically offset by derivatives — the net directional exposure is likely small. No trading action warranted.
Key Facts
- Bank of America Corporation crossed the 5% threshold on May 13, 2026, and notified Lakefront on May 20, 2026.
- Total reported economic interest is 9.30% of 65,897,071 outstanding shares.
- Direct voting rights are only 0.95% (623,434 shares); the remaining 8.35% is via equivalent financial instruments (5,502,802 instruments).
- The largest single instrument is a 'Right to Use' held by BofA Securities, Inc. representing 5,068,385 shares (7.69% of total).
- Other instruments include call options, swaps, and rights to recall held by Merrill Lynch International and Bank of America, National Association with various expiration dates through 2027.
- The disclosure is a Belgian transparency filing triggered by the acquisition of financial instruments treated as voting securities.
Financial Impact
No direct financial impact. The position appears to represent BofA's market-making, hedging, and derivatives book exposure, not a proprietary investment thesis.
Risk Factors
- If BofA's swap and derivatives positions are unwound, it could create temporary selling pressure in the underlying shares.
- The large 'Right to Use' position (7.69%) could imply a securities lending program, which may increase borrow availability and short interest capacity.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003711 |
| Document: f6k_052726.htm | 0001171843-26-003711 |
| Document: 0001171843-26-003711-index-headers.html | 0001171843-26-003711 |
| Document: 0001171843-26-003711-index.html | 0001171843-26-003711 |
| Document: 0001171843-26-003711.txt | 0001171843-26-003711 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access